Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eight-year European cancer biomarker project receives €10m funding

This article was originally published in Clinica

Executive Summary

The French innovation agency OSEO has injected €10m ($14.3m) into an eight-year research programme, IMAkinib, to develop specific biomarkers and radiotracers that would enable personalised and effective treatment for cancer patients. Heading the project, which is expected to cost €24.7m in total, is Oncodesign, a French oncology-focused biotech company. The firm will work together with fellow French companies Guerbet, which develops radiotracers for medical imaging procedures, and Ariana Pharmaceuticals, which specialises in data management software used to enhance the drug discovery and development process. Oncodesign will be responsible for developing the biomarkers specific to the drug treatments, while Guerbet will develop radiotracers. These radiotracers will be used in clinical trials for scanning tumours and to allow the evaluation of the drug's clinical efficacy. Ariana will provide the software for analysis of chemical and biological data.

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts